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Jeffrey D LifsonFigure 1 Michael Piatak, Jr., 2014.Michael Piatak, Jr, a talented, creative molecular virolo-
gist best known for his many contributions to develo-
ping methods for quantitative analysis of retroviral
nucleic acids, analyses central to many key advances in
AIDS research, passed away suddenly on 19 September
2014 at the age of 64 (Figure 1). His loss will be deeply felt
by the research community that benefitted profoundly
from his work over the past three decades, and from their
rewarding personal interactions with him over his career.
A proud undergraduate alumnus of Penn State (and
lifelong Nittany Lion football fan), Mike did his graduate
studies at Yale, receiving his PhD in Molecular Virology
in 1978, then continuing postdoctoral work at Yale with
Sherman Weisman, characterizing SV-40 transcripts and
replication in infected cells. Leaving Yale in 1982, he
moved to the Bay Area to join the early generation
biotechnology company Cetus Corporation. There, in
support of programs to generate monoclonal antibody-
based therapeutic immunotoxins, he cloned, character-
ized, and evaluated wild type and mutant forms of a
number of different plant derived ribosome inactivating
proteins, including pokeweed antiviral proteins, ricin,
and abrin, also developing recombinant systems for their
expression. It is a sign of the changed times in which we
live that the federal agency most likely to be interested
in such activities today would be the Department of
Homeland Security and not the Food and Drug Admin-
istration! Based on his expertise with the cloning and ex-
pression of plant derived ribosome inactivating proteins,
Mike was recruited in 1987 to join a small Bay Area bio-
tech startup, Genelabs Incorporated, which is where I
first met him, beginning a close professional and per-
sonal relationship that would extend over the next three
decades. At a time when therapeutic options for treating
HIV infection were limited, and unconventional thera-
peutic approaches were being pursued, the company was
investigating the potential utility of a plant derived protein,
trichosanthin, which had a long history of use in Chinese
traditional medicine and showed intriguing antiviral
activity in some in vitro HIV assay systems. AlthoughCorrespondence: Jeffrey.Lifson@nih.gov
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HIV infection, becoming a footnote in the history of
development of AIDS drugs, its evaluation triggered de-
velopments that have had a lasting impact on the field.
As a small underfunded startup, the company had nei-
ther the time nor money to support a large clinical trial
that could yield clinical endpoints to demonstrate drug
activity. Coming up with a means to assess drug activity
other than clinical endpoints was imperative. However,
at the time, surrogate markers for in vivo drug activity
or efficacy remained controversial, and available viro-
logic readouts such as viral culture, or plasma HIV p24
antigen levels were low to unmeasurable in many HIV
infected patients. It seemed like recently developed poly-
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most considered PCR to be a qualitative method only,
with the exponential amplification inherent to the tech-
nique also amplifying the impact of small experimental
vagaries to the point that the phrase “quantitative PCR” was
viewed as oxymoronic. With standard PCR methods, there
was not a consistent, predictable relationship between the
amount of amplified product at the end of the reaction and
the starting input amount of target template prior to ampli-
fication. Nevertheless, demonstrating the characteristics of
open mindedness, incisive critical and analytical thinking,
and dogged persistence that characterized the rest of his sci-
entific work, Mike set out to see if he could come up with a
way to tame PCR in a manner that would allow it to be used
for quantifying HIV RNA and DNA.
Impressed by a publication from Gary Gilliland and
Frank Bunn, in which they used a matched but internally
mutated and readily discriminated target template as an
internal control in a “competitive PCR” approach to try
to quantify levels of cytokine transcripts, basing quanti-
tation on the relative amounts of the two products in a
titration approach rather than absolute quantitation,
Mike worked to adapt this concept to quantifying HIV
targets, a task that entailed the additional challenge of
accommodating the sequence divergence in clinical isolates
of HIV. After much development effort and validation, we
were satisfied that we had a method, which we designated
“quantitative competitive PCR” (QC-PCR), that with con-
trol samples could sensitively and accurately quantify HIV
nucleic acids, publishing the method in BioTechniques in
1993. The key challenge was whether this method could
reliably be applied to clinical samples. We established a
collaboration with George Shaw and Mike Saag, who had a
large collection of impeccably pedigreed clinical samples
and conducted a blinded analysis. As detailed in a bench-
mark publication in Science in 1993, the assay worked,
detecting and quantifying viral RNA in the plasma of all
patients tested, including asymptomatic patients in whom
HIV p24 antigen and viral culture assays were negative.
Our determined viral RNA levels correlated with disease
stage and CD4+ T cell counts, and showed readily demon-
strable decreases in longitudinal specimens over the course
of resolution of primary infection or short term AZT
treatment. At a time when much of the field equated
the asymptomatic clinically latent phase of HIV infec-
tion with virologic latency, based on negative results in
HIV p24 antigen and viral culture assays, this publica-
tion, arguably more than any other, shifted the concep-
tual paradigm of HIV pathogenesis, recasting it as a
continuous battle of attrition between viral replication
and the immune system, and setting the stage for the
role of nucleic acid based virologic assessment of new
therapies as new drugs and combination therapies
became available.Following on the HIV QC-PCR publications, in response
to a request of whether we could provide a similar assay
for quantifying SIV in nonhuman primate (NHP) studies,
initially to assist in the analysis of a particular vaccine ex-
periment, Mike developed a SIV QC-PCR assay, which we
used to help Vanessa Hirsch and Bernie Moss demonstrate
modulation of virologic outcome in a study of a Modified
Vaccinia Ankara based vaccine, modulation which corre-
lated with prolonged survival, despite a failure to achieve
sterilizing protection. This set the stage for decades of sub-
sequent key contributions to AIDS research in NHP
models, providing quantitative virologic analyses for nu-
merous investigators across the country with increasingly
more sensitive and sophisticated assays, including early
adoption of higher throughput real time quantitative PCR
methods when the necessary reagents and instrumentation
became available, and the more recent development of ex-
quisitely sensitive methods to meet the emerging demands
of evaluating HIV cure strategies in NHP models.
Mike was a rare scientist, more interested in coming
up with a better way to solve an analytical challenge with
a new assay once someone had convinced him that such
an assay was important for addressing a significant issue
in AIDS research, than with trying to decide himself
what the interesting questions were that needed to be
addressed. And he was far more interested in answering
such questions than worrying about who got credit for
answering them. His pragmatism for getting the job
done however, was tempered by a strong instinct, when-
ever possible, to prefer the more elegant solution to a
given problem. The only times we ever disagreed profes-
sionally were when I felt that a newly developed assay,
version n, was ready to be applied to real samples from
the actual experiment that had driven the development
of the assay, and Mike felt yet another refinement, ver-
sion n + 1, could make it even better. He was almost al-
ways right.
Both Mike and I left California for Maryland in 1995,
with Mike doing a 2 year stint working on DNA Diagnos-
tics at Becton Dickinson before rejoining me where I had
relocated to the AIDS and Cancer Virus Program (then
the AIDS Vaccine Program) at the Frederick National La-
boratory (then known as the National Cancer Institute at
Frederick). In keeping with the mission of the Frederick
National Laboratory to serve as a national resource for the
research community, for the next 17 years Mike provided
investigators with unparalleled quantitative virologic sup-
port of studies in NHP models, and more recently in vari-
ous clinical studies that demanded ultrasensitive analyses
of specimens from HIV infected patients. Beyond the tech-
nical rigor, innovative creativity and deep analytical insight
that Mike brought to the development and application of
assays to support these studies, often developing custom
analyses to address study specific requirements, his efforts
doi:10.1186/s12977-014-0092-x
Cite this article as: Lifson: Obituary: Remembering Michael Piatak, Jr.
Retrovirology 2014 11:92.
Lifson Retrovirology 2014, 11:92 Page 3 of 3
http://www.retrovirology.com/content/11/1/92were characterized by an extraordinary commitment to
meeting the needs of collaborating investigators, whether
for development of new, seemingly impossible assays to
meet emerging experimental requirements, or delivering
data to meet unreasonable short notice deadlines tied to
submission of grants, abstracts, or manuscripts. Indeed,
with reference to his commitment to supporting increas-
ingly demanding needs of collaborators, it was half in jest
and half as a cautionary tale that I gave Mike a copy of the
classic children’s book If You Give a Mouse a Cookie,
which begins “If you give a mouse a cookie, he's going to
ask for a glass of milk. When you give him the milk, he'll
probably ask you for a straw. When he's finished, he'll ask
you for a napkin”. then continues on in kind for many
more pages! The book wound up being prominently dis-
played in Mike’s lab, but the collaborators always got their
cookie, and their milk, with a straw, and usually with a
nicer napkin than they were expecting, because Mike
understood the importance of answering the questions
they were posing. Perhaps nowhere was this as true as in
his painstaking efforts in recent collaborative studies with
Louis Picker for which he developed exquisitely sensitive
assays to detect any residual virus in tissues from ma-
caques in which we were able to show that responses to a
CMV-vectored SIV vaccine were capable of controlling
and ultimately clearing an established infection with a
pathogenic SIV. Leading by example, he inspired the same
level of dedication and commitment in the members of his
laboratory.
Mike’s generosity extended to training investigators
from other laboratories in quantitative PCR methods,
sharing reagents, expertise and troubleshooting advice.
Indeed the one bittersweet silver lining in having the sad
task of notifying colleagues across the country of Mike’s
sudden passing was the flood of e-mails I received in re-
turn, virtually all variations on the tripartite theme of
sad, shocked disbelief, grateful acknowledgement of the
many key enabling contributions Mike had made to their
work, and comments that in addition to their appreci-
ation of his professional contributions, it was Mike’s
personal characteristics of warm, good natured, patient,
generous, thoughtful humanity that they will remember
and miss.
Mike brought those same attributes to his deep in-
volvement in his community and multiple charitable or-
ganizations, and his commitment to his family. Indeed,
just days before Mike died, his daughter, enrolled in a
master’s degree program, was scheduled to give her first
ever conference presentation at a meeting in Florida.
She was nervous, in part because it was her first presen-
tation and she was the most junior and inexperienced
presenter on the program. Mike supported and coached
her from a distance, and much to her delight, moments
after concluding her successful presentation, her cellphone rang with a surprise congratulatory phone call
from her dad, who, in the midst of an incredibly hectic,
demanding schedule, had found the time to look up the
conference presentation schedule online and make sure
to call her to celebrate just after she finished her presen-
tation. That was the kind of man he was, in the lab and
at home, and he will be profoundly missed.
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